Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMC 2359680)

Published in Br J Cancer on December 18, 2007

Authors

B Nisman1, H Biran, N Heching, V Barak, N Ramu, I Nemirovsky, T Peretz

Author Affiliations

1: Department of Oncology, Hadassah University Hospital, Jerusalem, Israel. nisman@hadassah.org.il

Articles by these authors

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83

Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28

Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol (1991) 2.08

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol (2000) 1.98

Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69

Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol (1996) 1.59

Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52

Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis (2010) 1.52

Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology (1999) 1.49

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41

Screening for prostate cancer. Isr J Med Sci (1995) 1.38

Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis (1995) 1.34

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer (1998) 1.32

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27

Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun (1996) 1.24

The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet (1999) 1.19

Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril (1996) 1.16

Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis (2010) 1.15

The secretion of PGE2, IL-1 beta, IL-6, and TNF alpha by adherent mononuclear cells from early onset periodontitis patients. J Periodontol (1994) 1.13

Constitutive secretion of interleukin 1 by human monocytes. Eur J Immunol (1983) 1.12

Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer (2006) 1.12

Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. Am J Obstet Gynecol (2001) 1.12

The isolation and purification of human peripheral blood monocytes in cell suspension. J Immunol Methods (1980) 1.08

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood (1996) 1.08

Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07

Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol (1992) 1.05

Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience. Prenat Diagn (2009) 1.05

Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia (2001) 1.04

Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol (1986) 1.03

Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer (2013) 1.02

Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer (1991) 1.02

Primary colorectal sarcoma. A retrospective review and prognostic factor study of 50 consecutive patients. Arch Surg (1990) 1.00

Identification of interleukin-2 in human peripheral blood eosinophils. Immunology (1996) 0.99

Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol (1989) 0.98

Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod (1996) 0.98

Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril (1997) 0.97

Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res (1999) 0.97

Eosinophilic granuloma of the spine. J Pediatr Orthop B (1997) 0.96

Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) (2007) 0.96

Activation of murine macrophages by lipoprotein and lipooligosaccharide of Treponema denticola. Infect Immun (1999) 0.95

A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: a possible role of the Alu-polyA tail in the evolution of the deletion. Genes Chromosomes Cancer (2001) 0.95

Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril (1996) 0.94

Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy. J Clin Oncol (1990) 0.92

Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered (2001) 0.91

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer (2004) 0.91

Relaxation of imprinting in trophoblastic disease. Gynecol Oncol (1994) 0.90

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer (2002) 0.90

Interleukin-1 activity in lesioned peripheral nerve. J Neuroimmunol (1992) 0.90

The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. Cancer (1994) 0.90

EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene (2013) 0.90

Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (1994) 0.90

Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet (1998) 0.90

Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol (2003) 0.90

Percutaneous image-guided needle biopsy in children--summary of our experience with 57 children. Pediatr Radiol (2001) 0.89

Establishment of cell lines from somatic cell hybrids between human monocytes and mouse myeloma cells. J Immunol (1984) 0.89

Phosphorylation of a K+ channel alpha subunit modulates the inactivation conferred by a beta subunit. Involvement of cytoskeleton. J Biol Chem (1996) 0.89

H19 expression and tumorigenicity of choriocarcinoma derived cell lines. Oncogene (1995) 0.89

No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. Cancer Res (1998) 0.88

Metastatic placental site trophoblastic tumors: clinical aspects of two unique cases. Acta Obstet Gynecol Scand (2001) 0.88

The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet (1998) 0.88

Selection and continuous growth of antigen-specific human T cells by antigen-treated monocytes. Eur J Immunol (1983) 0.87

Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer (2008) 0.87

Sulfate moieties in the subendothelial extracellular matrix are involved in basic fibroblast growth factor sequestration, dimerization, and stimulation of cell proliferation. J Biol Chem (1996) 0.86

High oxygen concentration exacerbates cardiopulmonary bypass-induced lung injury. J Cardiothorac Vasc Anesth (2000) 0.86

Transmission of response to trauma? Second-generation Holocaust survivors' reaction to cancer. Am J Psychiatry (2000) 0.86

Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol (1997) 0.86

Plasma vascular endothelial growth factor level is a predictor of the severity of postoperative capillary leak syndrome in neonates undergoing cardiopulmonary bypass. Pediatr Surg Int (2002) 0.85

Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs (1998) 0.85

Laminarin sulfate mimics the effects of heparin on smooth muscle cell proliferation and basic fibroblast growth factor-receptor binding and mitogenic activity. J Cell Physiol (1995) 0.85

Ocular and orbital complications following the treatment of retinoblastoma. Eur J Ophthalmol (1998) 0.85

Psychological intervention in cancer patients: a randomized study. Gen Hosp Psychiatry (2001) 0.85

Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis Rheum (1998) 0.84

Repeat bacterial challenge in a subcutaneous chamber model results in augmented tumour necrosis factor-alpha and interferon-gamma response, and suppression of interleukin-10. Immunology (2000) 0.84

Serum levels of interleukin-2 receptor in ocular Behçet's disease. Am J Ophthalmol (1993) 0.84

Leptomeningeal metastases: evaluation by gadolinium enhanced spinal magnetic resonance imaging. J Neurooncol (1998) 0.84

Perception of ill spouse and dyadic relationship in couples with affective disorder and those without. J Affect Disord (2000) 0.84

Regulation of RCK1 currents with a cAMP analog via enhanced protein synthesis and direct channel phosphorylation. J Biol Chem (1995) 0.84

Rapid fluorometric quantification of monocyte attachment in tissue culture wells. J Immunol Methods (1993) 0.83

Recombinant human interleukin-1 suppresses lipoprotein lipase activity, but not expression of lipoprotein lipase mRNA in mesenchymal rat heart cell cultures. Biochim Biophys Acta (1991) 0.83

Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. Arthritis Rheum (1999) 0.83

Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant (1995) 0.83

Reduced ouabain-sensitive potassium entry as a possible mechanism of multidrug-resistance in P388 cells. Biochem Pharmacol (1991) 0.83

Increased serum concentrations of interleukin-1 beta in patients with coronary artery disease. Heart (1996) 0.83

Effects of tetracyclines on the pathologic activity of endotoxin: in vitro and in vivo studies. Adv Dent Res (1998) 0.83

Interleukin-6 secretion in mice is associated with reduced glucose-6-phosphatase and liver glycogen levels. Am J Physiol (1997) 0.83

The Effect of Genetic Counseling on Knowledge and Perceptions Regarding Risks for Breast Cancer. J Genet Couns (1998) 0.82

Holocaust cancer patients: a comparative study. Psychiatry (1993) 0.82

Increased levels of basic fibroblast growth factor are found in the cross-clamped heart during cardiopulmonary bypass. Can J Cardiol (2000) 0.82

Serum basic fibroblast growth factor levels in patients with ischemic heart disease. Int J Cardiol (1997) 0.82

Episodic angioedema with eosinophilia: a case associated with T cell activation and cytokine production. Ann Allergy (1993) 0.82

Human monocyte response to cementum extracts from periodontally diseased teeth: effect of conditioning with tetracycline. J Periodontol (1996) 0.82

Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expr Purif (2004) 0.82

Tumor necrosis factor inhibits the transcriptional rate of glucose-6-phosphatase in vivo and in vitro. Metabolism (1997) 0.82

Inactivation of a voltage-dependent K+ channel by beta subunit. Modulation by a phosphorylation-dependent interaction between the distal C terminus of alpha subunit and cytoskeleton. J Biol Chem (1997) 0.82

Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Exp Hematol (2001) 0.82

Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J Hematother Stem Cell Res (2001) 0.82